Statins promote potent systemic antioxidant effects through specific inflammatory pathways - PubMed (original) (raw)
Clinical Trial
. 2003 Jul 29;108(4):426-31.
doi: 10.1161/01.CIR.0000080895.05158.8B. Epub 2003 Jul 14.
Affiliations
- PMID: 12860913
- DOI: 10.1161/01.CIR.0000080895.05158.8B
Clinical Trial
Statins promote potent systemic antioxidant effects through specific inflammatory pathways
Mehdi H Shishehbor et al. Circulation. 2003.
Abstract
Background: The pleiotropic actions of hydroxymethylglutaryl CoA reductase inhibitors (statins) include antiinflammatory and antioxidant actions. We recently reported that statins induce reductions in plasma protein levels of nitrotyrosine (NO2Tyr), a modification generated by nitric oxide-derived oxidants. Whether alternative oxidative pathways are suppressed in vivo after statin administration has not yet been reported.
Methods and results: As an extension of our prior study, hypercholesterolemic subjects with no known coronary artery disease were evaluated at baseline and after 12 weeks of atorvastatin therapy (10 mg/d). Plasma levels of protein-bound chlorotyrosine, NO2Tyr, dityrosine, and orthotyrosine, specific molecular fingerprints for distinct oxidative pathways upregulated in atheroma, were determined by mass spectrometry. In parallel, alterations in lipoproteins and C-reactive protein were determined. Statin therapy caused significant reductions in chlorotyrosine, NO2Tyr, and dityrosine (30%, 25%, and 32%, respectively; P<0.02 each) that were similar in magnitude to reductions in total cholesterol and apolipoprotein B-100 (25% and 29%, P<0.001 each). Nonsignificant decreases in orthotyrosine and C-reactive protein levels were observed (9% and 11%, respectively; P>0.10 each). Statin-induced reductions in oxidation markers were independent of decreases in lipids and lipoproteins.
Conclusions: Statins promote potent systemic antioxidant effects through suppression of distinct oxidation pathways. The major pathways inhibited include formation of myeloperoxidase-derived and nitric oxide-derived oxidants, species implicated in atherogenesis. The present results suggest potential mechanisms that may contribute to the beneficial actions of statins. They also have important implications for monitoring the antiinflammatory and antioxidant actions of these agents.
Similar articles
- Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Haendeler J, et al. Circulation. 2004 Aug 17;110(7):856-61. doi: 10.1161/01.CIR.0000138743.09012.93. Epub 2004 Aug 2. Circulation. 2004. PMID: 15289372 - Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL. Shishehbor MH, et al. JAMA. 2003 Apr 2;289(13):1675-80. doi: 10.1001/jama.289.13.1675. JAMA. 2003. PMID: 12672736 - Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.
John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. John S, et al. Am Heart J. 2005 Mar;149(3):473. doi: 10.1016/j.ahj.2004.06.027. Am Heart J. 2005. PMID: 15864218 Clinical Trial. - Early vascular benefits of statin therapy.
Tsiara S, Elisaf M, Mikhailidis DP. Tsiara S, et al. Curr Med Res Opin. 2003;19(6):540-56. doi: 10.1185/030079903125002225. Curr Med Res Opin. 2003. PMID: 14594527 Review. - Beneficial cardiovascular pleiotropic effects of statins.
Davignon J. Davignon J. Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43. doi: 10.1161/01.CIR.0000131517.20177.5a. Circulation. 2004. PMID: 15198965 Review.
Cited by
- Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell.
Morotti A, Barale C, Melchionda E, Russo I. Morotti A, et al. Int J Mol Sci. 2022 Sep 28;23(19):11446. doi: 10.3390/ijms231911446. Int J Mol Sci. 2022. PMID: 36232746 Free PMC article. Review. - Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.
Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Zheng L, et al. J Clin Invest. 2004 Aug;114(4):529-41. doi: 10.1172/JCI21109. J Clin Invest. 2004. PMID: 15314690 Free PMC article. - Pleiotropic effects of statins in atrial fibrillation patients: the evidence.
Hadi HA, Mahmeed WA, Suwaidi JA, Ellahham S. Hadi HA, et al. Vasc Health Risk Manag. 2009;5(3):533-51. doi: 10.2147/vhrm.s4841. Epub 2009 Jun 29. Vasc Health Risk Manag. 2009. PMID: 19590588 Free PMC article. Review. - Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
Shishehbor MH, Hazen SL. Shishehbor MH, et al. Cleve Clin J Med. 2009 Jan;76(1):37-44. doi: 10.3949/ccjm.75a.08105. Cleve Clin J Med. 2009. PMID: 19122109 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials